Headlines about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a coverage optimism score of 0.44 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.3052162089404 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Separately, ValuEngine downgraded Biostar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 9th.

TRADEMARK VIOLATION NOTICE: This story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/09/26/biostar-pharmaceuticals-bspm-receiving-favorable-media-coverage-accern-reports.html.

Biostar Pharmaceuticals Company Profile

Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).

Insider Buying and Selling by Quarter for Biostar Pharmaceuticals (NASDAQ:BSPM)

Receive News & Ratings for Biostar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.